

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on NOV 8 2010

TOWNSEND and TOWNSEND and CREW LLP

By: Allen Hill

PATENT  
Attorney Docket No.: 082368-006600US  
Client Ref. No.: M3-A0301Y1P-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Yousuke EBINA et al.

Application No.: 10/554,561

Filed: April 15, 2004

For: METHODS FOR MEASURING  
THE INSULIN RECEPTOR ALPHA  
SUBUNIT

Customer No.: 20350

Confirmation No. 5776

Examiner: Woodward, Cherie Michelle

Technology Center/Art Unit: 1647

REQUEST FOR CERTIFICATE OF  
CORRECTION UNDER 37 C.F.R. § 1.322

Attn: Certificate of Corrections Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

Pursuant to 37 C.F.R. § 1.322, Applicants submit a Certificate of Correction for the above-identified patent. The desired correction is set forth on the attached PTO/SB/44 form. Applicants submit that the correction of the mistake does not materially affect the scope or meaning of the patent, constitute new matter or require reexamination. The requested change is shown below:

(54) METHODS FOR MEASURING THE INSULIN RECEPTOR [[α]] ALPHA.

U.S. Patent No. 7,766,895  
Request for Certificate of Correction  
Page Two

Applicants further submit that the mistake is on the part of the Office, as evidenced by the correction made in the Preliminary Amendment filed on October 24, 2005, a copy of which is attached for convenience of reference.. Thus, applicants believe no fee is due.

Respectfully submitted,

  
Kevin L. Baslan  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
Attachments  
KLB:dk  
62953197 v1

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**Page 1 of 1

PATENT NO. : 7,732,154  
APPLICATION NO.: PCT/JP04/005412  
ISSUE DATE : June 8, 2010  
INVENTOR(S) : Yousuke Ebina et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face page, in the title (54), delete á and insert ALPHA therefor.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

TOWNSEND AND TOWNSEND AND CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, CA 94111-3834

"Express Mail" Label No. EV 569269978 US  
Date of Deposit October 25, 2005

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By:   
Aaron Hokamura

PATENT  
Attorney Docket No.: 082368-006600US  
Client Ref. No.: M3-A0301Y1P-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Yousuke EBINA et al.

Application No.:

Filed:

Int'l Application No.: PCT/JP04/005412

Int'l Filing Date: April 15, 2004

For: METHODS FOR MEASURING  
THE INSULIN RECEPTOR ALPHA  
SUBUNIT (as amended)

Customer No.: 20350

Confirmation No.

Examiner:

Technology Center/Art Unit:

PRELIMINARY AMENDMENT

AND

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith a Sequence Listing in paper and computer readable forms.

Prior to examination of the above-referenced application, please enter the following amendments and remarks:

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks/Arguments** begin on page 4 of this paper.

**Amendments to the Specification:**

Please amend the title as follows:

"METHOD OF METHODS FOR MEASURING THE INSULIN RECEPTOR ALPHA  $\alpha$   
SUBUNIT"

Please amend the paragraph on page 12, lines 30-31, beginning, "Fluorescent substances:..." as follows:

--Fluorescent substances:

fluorescein isothiocyanate,  
tetramethylrhodamine isothiocyanate,  
substituted rhodamine isothiocyanate,  
dichlorotriazine isothioeyanate fluorescein, etc.--

Please amend the paragraph on page 23, lines 13-16, beginning, "Fig. 5 is a graph showing over-time changes in blood glucose level in mice to which the..." as follows:

--Fig. 5 is a graph showing over-time changes in blood glucose level in mice to which the insulin receptor  $\alpha$ -subunit has been administered. In the figure, the vertical axis indicates the blood glucose level (mg/dL) (~~mg/mL~~), and the horizontal axis indicates the time elapsed (in minutes) where the time of insulin receptor  $\alpha$ -subunit administration is set as -10.--

Please amend the paragraph on page 23, lines 17-21, beginning, "Fig. 6 is a graph showing the over-time changes in blood glucose level in mice to which..." as follows:

--Fig. 6 is a graph showing the over-time changes in blood glucose level in mice to which a glucose load has been given 10 minutes after administration of the insulin receptor  $\alpha$ -subunit. In the figure, the vertical axis indicates the blood glucose level (mg/dL) (~~mg/mL~~), and the horizontal axis indicates the time elapsed (in minutes) where the time of insulin receptor  $\alpha$ -subunit administration is set as -10.--

**REMARKS/ARGUMENTS**

Applicants respectfully request entry of this amendment.


The amendment to the title is made to more clearly describe the subject matter of the instant application and adds no new matter.

The amendments to the specification merely correct errors in the Japanese specification, which would be apparent to one skilled in the relevant art, from other descriptions in the specification or from common technical knowledge. In particular, paragraph 12 is amended from "dichlorotriazine isothiocyanate" to "dichlorotriazine fluorescein". One of skill in the art would recognize that there is no compound "dichlorotriazine isothiocyanate" and that "dichlorotriazine fluorescein" is a common fluorescent label. Support for the amendments to the paragraphs on page 23 can be found in figures 5 and 6. Support for the amendment to the paragraph on page 28 can be found in Table 1 on the same page. Therefore, no new matter is added.

A Sequence Listing on paper and in computer readable form was prepared in accordance with 37 C.F.R. §§1.821 to 1.825, and is submitted herewith. The Sequence Listing does not include new matter or matter that goes beyond the disclosure of the International Application. The information contained in the computer readable disk was prepared through the use of the software program "FastSeq" and is identical to that of the paper copy of the Sequence Listing.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

  
Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:ath  
00618259 v1